Form 4: Skye Bioscience CFO Kaitlyn Arsenault Reports Stock Option Grant

Kaitlyn Arsenault, CFO of Skye Bioscience, Inc., reports the acquisition of stock options.

Summary

• On February 24, 2025, Kaitlyn Arsenault, the Chief Financial Officer of Skye Bioscience, Inc., was granted stock options to purchase 150,000 shares of common stock.
• The exercise price of these options is $2.89 per share.
• The options vest in equal monthly installments over a four-year period, commencing on February 21, 2025, and expire on February 25, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is neither particularly positive nor negative.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Comparable companies often use similar vesting schedules (e.g., monthly or quarterly over a 3-4 year period).
• The size of the grant is likely determined by a number of factors including the executive's role, company size, and overall compensation strategy.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CFO.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates